CYCN Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are designed to target tissues of greatest relevance to the diseases they are intended to treat.

As of 10/04/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/02/2019
Outstanding shares:  43,448,360
Average volume:  114,575
Market cap:   $37,365,590
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -0.77
PB ratio:   1.06
PS ratio:   9.10
Return on equity:   -138.32%
Net income %:   -1,247.56%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy